{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:13:16Z","timestamp":1789243996055,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204697\/Z\/16\/Z"],"award-info":[{"award-number":["204697\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["217105\/Z\/19\/Z"],"award-info":[{"award-number":["217105\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.pt.2024.07.003","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T21:10:12Z","timestamp":1722892212000},"page":"820-828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pass the boron: benzoxaboroles as antiparasite drugs"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-285X","authenticated-orcid":false,"given":"Martin","family":"Zoltner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5173-9284","authenticated-orcid":false,"given":"David","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-2885","authenticated-orcid":false,"given":"Mark C.","family":"Field","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2024.07.003_bb0005","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S2214-109X(22)00338-2","article-title":"Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2-3 trial","volume":"10","author":"Betu Kumesu","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.pt.2024.07.003_bb0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1473-3099(22)00660-0","article-title":"Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2\/3 trial","volume":"23","author":"Betu Kumesu","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pt.2024.07.003_bb0015","series-title":"World Malaria Report 2023","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.pt.2024.07.003_bb0020","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pt.2024.07.003_bb0025","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor Velcade (Bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Investig."},{"key":"10.1016\/j.pt.2024.07.003_bb0030","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1016\/j.bmc.2014.04.065","article-title":"The unique chemistry of benzoxaboroles: current and emerging applications in biotechnology and therapeutic treatments","volume":"22","author":"Liu","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pt.2024.07.003_bb0035","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/ph15030264","article-title":"The boron advantage: the evolution and diversification of boron's applications in medicinal chemistry","volume":"15","author":"Messner","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pt.2024.07.003_bb0040","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1021\/jm0603724","article-title":"Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis","volume":"49","author":"Baker","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2024.07.003_bb0045","series-title":"The New York Times","author":"Picker","year":"2016"},{"key":"10.1016\/j.pt.2024.07.003_bb0050","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/ml100013s","article-title":"Discovery of novel benzoxaborole-based potent antitrypanosomal agents","volume":"1","author":"Ding","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.pt.2024.07.003_bb0055","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.bmcl.2010.12.034","article-title":"Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents","volume":"21","author":"Zhang","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pt.2024.07.003_bb0060","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.pt.2018.04.002","article-title":"Melarsoprol resistance in African trypanosomiasis","volume":"34","author":"Fairlamb","year":"2018","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2024.07.003_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41579-022-00777-y","article-title":"Anti-trypanosomatid drug discovery: progress and challenges","volume":"21","author":"De Rycker","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.pt.2024.07.003_bb0070","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.pt.2023.01.010","article-title":"Drug discovery for parasitic diseases: powered by technology, enabled by pharmacology, informed by clinical science","volume":"39","author":"Rao","year":"2023","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2024.07.003_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001151","article-title":"SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis","volume":"5","author":"Jacobs","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.003_bb0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bmcl.2017.11.028","article-title":"Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African trypanosomiasis (AAT)","volume":"28","author":"Akama","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pt.2024.07.003_bb0090","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41564-022-01211-y","article-title":"Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates","volume":"7","author":"Padilla","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.pt.2024.07.003_bb0095","doi-asserted-by":"crossref","first-page":"16159","DOI":"10.1021\/acs.jmedchem.1c01437","article-title":"DNDI-6148: a novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis","volume":"64","author":"Mowbray","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2024.07.003_bb0100","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.3390\/microorganisms9071408","article-title":"Identification of resistance determinants for a promising antileishmanial oxaborole series","volume":"9","author":"Van den Kerkhof","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.pt.2024.07.003_bb0105","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1128\/AAC.00820-16","article-title":"Antimalarial benzoxaboroles target Plasmodium falciparum leucyl-tRNA synthetase","volume":"60","author":"Sonoiki","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2024.07.003_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7161","article-title":"Metal-captured inhibition of pre-mRNA processing activity by CPSF3 controls Cryptosporidium infection","volume":"11","author":"Swale","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2024.07.003_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14574","article-title":"A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue","volume":"8","author":"Sonoiki","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2024.07.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.132057","article-title":"Benzoxaboroles: new emerging and versatile scaffold with a plethora of pharmacological activities","volume":"1252","author":"Dhawan","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.pt.2024.07.003_bb0125","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201800025","article-title":"Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA","volume":"1","author":"Xia","year":"2018","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.pt.2024.07.003_bb0130","doi-asserted-by":"crossref","first-page":"11379","DOI":"10.1021\/acs.jmedchem.1c00717","article-title":"High-throughput crystallography reveals boron-containing inhibitors of a penicillin-binding protein with di- and tricovalent binding modes","volume":"64","author":"Newman","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2024.07.003_bb0135","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1016\/j.febslet.2012.07.058","article-title":"Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center","volume":"586","author":"Freund","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.pt.2024.07.003_bb0140","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.bmcl.2009.03.007","article-title":"Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis","volume":"19","author":"Akama","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pt.2024.07.003_bb0145","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","volume":"316","author":"Rock","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.pt.2024.07.003_bb0150","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1128\/AAC.02058-12","article-title":"Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria","volume":"57","author":"Hernandez","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2024.07.003_bb0155","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1128\/AAC.01339-16","article-title":"Discovery of novel oral protein synthesis inhibitors of Mycobacterium tuberculosis that target leucyl-tRNA synthetase","volume":"60","author":"Palencia","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2024.07.003_bb0160","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41591-024-02829-7","article-title":"A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial","volume":"30","author":"Diacon","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.pt.2024.07.003_bb0165","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-022-01817-w","article-title":"The struggle to end a millennia-long pandemic: novel candidate and repurposed drugs for the treatment of tuberculosis","volume":"82","author":"Edwards","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.pt.2024.07.003_bb0170","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1128\/AAC.00873-16","article-title":"Cryptosporidium and Toxoplasma parasites are inhibited by a benzoxaborole targeting leucyl-tRNA synthetase","volume":"60","author":"Palencia","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2024.07.003_bb0175","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jmb.2009.04.073","article-title":"Crystal structures of the human and fungal cytosolic leucyl-tRNA synthetase editing domains: a structural basis for the rational design of antifungal benzoxaboroles","volume":"390","author":"Seiradake","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.pt.2024.07.003_bb0180","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1021\/jacs.2c04808","article-title":"Adenosine-dependent activation mechanism of prodrugs targeting an aminoacyl-tRNA synthetase","volume":"145","author":"Hoffmann","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.pt.2024.07.003_bb0185","doi-asserted-by":"crossref","first-page":"385","DOI":"10.15252\/emmm.201607370","article-title":"Targeting Toxoplasma gondii CPSF3 as a new approach to control toxoplasmosis","volume":"9","author":"Palencia","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.pt.2024.07.003_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101871","article-title":"Target identification of an antimalarial oxaborole identifies AN13762 as an alternative chemotype for targeting CPSF3 in apicomplexan parasites","volume":"23","author":"Bellini","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.pt.2024.07.003_bb0195","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.1073\/pnas.1807915115","article-title":"Clinical and veterinary trypanocidal benzoxaboroles target CPSF3","volume":"115","author":"Wall","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2024.07.003_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007315","article-title":"The trypanocidal benzoxaborole AN7973 inhibits trypanosome mRNA processing","volume":"14","author":"Begolo","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2024.07.003_bb0205","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13104-022-06258-y","article-title":"Clinically relevant benzoxaboroles inhibit mRNA processing in Trypanosoma brucei","volume":"15","author":"Waithaka","year":"2022","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.pt.2024.07.003_bb0210","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pt.2023.03.015","article-title":"Effective drug discovery in Chagas disease","volume":"39","author":"Tarleton","year":"2023","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2024.07.003_bb0215","article-title":"Targeted protein degradation of the CPSF complex by benzoxaboroles through sumoylation","author":"Zhang","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.pt.2024.07.003_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012166","article-title":"Depolymerization of SUMO chains induces slender to stumpy differentiation in T. brucei bloodstream parasites","volume":"20","author":"Iribarren","year":"2024","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2024.07.003_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj0123","article-title":"Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer","volume":"9","author":"Shen","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.pt.2024.07.003_bb0230","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.chembiol.2023.10.019","article-title":"Anticancer benzoxaboroles block pre-mRNA processing by directly inhibiting CPSF3","volume":"31","author":"Tao","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.pt.2024.07.003_bb0235","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/plphys\/kiad352","article-title":"Inhibitor AN3661 reveals biological functions of Arabidopsis cleavage and polyadenylation specificity factor 73","volume":"193","author":"Hao","year":"2023","journal-title":"Plant Physiol."},{"key":"10.1016\/j.pt.2024.07.003_bb0240","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.molcel.2009.04.024","article-title":"A core complex of CPSF73, CPSF100, and Symplekin may form two different cleavage factors for processing of poly(A) and histone mRNAs","volume":"34","author":"Sullivan","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.pt.2024.07.003_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103047","article-title":"An examination of the metal ion content in the active sites of human endonucleases CPSF73 and INTS11","volume":"299","author":"Huang","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pt.2024.07.003_bb0250","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkac319","article-title":"Oligo targeting for profiling drug resistance mutations in the parasitic trypanosomatids","volume":"50","author":"Altmann","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.pt.2024.07.003_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006850","article-title":"Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles","volume":"14","author":"Zhang","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2024.07.003_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008932","article-title":"Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs","volume":"16","author":"Giordani","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2024.07.003_bb0265","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02640-19","article-title":"Plasmodium falciparum resistance to a lead benzoxaborole due to blocked compound activation and altered ubiquitination or sumoylation","volume":"11","author":"Sindhe","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.pt.2024.07.003_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006386","article-title":"Prospective evaluation of a rapid diagnostic test for Trypanosoma brucei gambiense infection developed using recombinant antigens","volume":"12","author":"Lumbala","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2024.07.003_bb0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-3305-1-3","article-title":"The history of African trypanosomiasis","volume":"1","author":"Steverding","year":"2008","journal-title":"Parasit. Vectors"},{"key":"10.1016\/j.pt.2024.07.003_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009965","article-title":"Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline","volume":"17","author":"Sullivan","year":"2021","journal-title":"PLoS Pathog."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149222400179X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149222400179X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T13:17:23Z","timestamp":1725542243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149222400179X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S147149222400179X"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2024.07.003","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pass the boron: benzoxaboroles as antiparasite drugs","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2024.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}